Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nippon Zoki licenses renal product to Hyundai

This article was originally published in Scrip

Executive Summary

The Japanese firm Nippon Zoki has licensed its renal protective agent NZ-419 to Hyundai Pharmaceuticals for exclusive development and marketing in South Korea. Hyundai plans to begin local clinical trials in chronic kidney disease (CKD) patients next year and to launch the product in 2014. NZ-419 acts to remove damaging hydroxyl active radicals to slow or prevent deterioration in kidney function and delay the need for maintenance dialysis. Nippon Zoki noted that around 5% of adult CKD patients are at high risk of end-stage renal disease and that there are some 1.6 million potential CKD patients in South Korea. 45,000 people in the country were on maintenance dialysis at the end of 2006. Nippon Zoki retains development and sales rights to NZ-419 in Japan, the US and Europe.

You may also be interested in...

Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon

Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.

Asia Executives On The Move: Sanofi's Global R&D Head Moves To Innovent

Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts